1-4 of 4
David Wei
Close
Sort by
Journal Articles

Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US)

Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav
Journal: Blood
Blood (2023) 142 (Supplement 1): 5190.
https://doi.org/10.1182/blood-2023-180789
Published: 2023
Journal Articles

Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Asciminib in US Clinical Practice

Ehab L. Atallah, David Wei, Dominick Latremouille-Viau, Carmine Rossi, Andrea Damon, Germano Ferreira, Annie Guerin, Kejal Jadhav
Journal: Blood
Blood (2023) 142 (Supplement 1): 1809.
https://doi.org/10.1182/blood-2023-178722
Published: 2023
Journal Articles

Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US)

Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav
Journal: Blood
Blood (2023) 142 (Supplement 1): 5098.
https://doi.org/10.1182/blood-2023-180772
Published: 2023
Journal Articles

Recurrent and Refractory Hemophagocytic Lymphohistiocytosis in an Elderly. Role of Immune Aberration Due to Myeloid Gene Mutation

Suthanthira kannan Ramamoorthy, MDFRCPA,FRCP, Tina Noutsos, BS,MBBS,FRACP,FRCPA, David Wei, MBBS,FRCPA, Alexandra Yasmin Laidman, MBBS, Ferenc Szabo, FRACP,FRCPA
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–26.
https://doi.org/10.1182/blood-2020-133776
Published: 2020